{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:16:04Z","timestamp":1792498564059,"version":"4.5.0"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,1,19]]},"DOI":"10.1248\/bpb.b23-00667","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T22:11:28Z","timestamp":1705615888000},"page":"196-203","source":"Crossref","is-referenced-by-count":12,"title":["Development of an Effective Psoriasis Treatment by Combining Tacrolimus-Encapsulated Liposomes and Iontophoresis"],"prefix":"10.1248","volume":"47","author":[{"given":"Seiko","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Health Chemistry, Graduate School of Pharmaceutical Sciences, Tokushima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizune","family":"Ozono","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Chemistry, Graduate School of Biomedical Sciences, Tokushima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yanagi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Chemistry, Faculty of Pharmaceutical Sciences, Tokushima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kogure","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Chemistry, Graduate School of Biomedical Sciences, Tokushima University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Voorhees JJ, Abecasis GR, Nair RP. Molecular dissection of psoriasis: integrating genetics and biology. <i>J. Invest. Dermatol.<\/i>, <b>130<\/b>, 1213\u20131226 (2010).","DOI":"10.1038\/jid.2009.319"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-\u03baB: an essential transcription factor in psoriasis. <i>J. Dermatol. Sci.<\/i>, <b>69<\/b>, 89\u201394 (2013).","DOI":"10.1016\/j.jdermsci.2012.11.002"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. <i>Clin. Med. <\/i>(Lond.), <b>21<\/b>, 170\u2013173 (2021).","DOI":"10.7861\/clinmed.2021-0257"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Prausnitz MR, Langer R. Transdermal drug delivery. <i>Nat. Biotechnol.<\/i>, <b>26<\/b>, 1261\u20131268 (2008).","DOI":"10.1038\/nbt.1504"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zhang Z, Tsai PC, Ramezanli T, Michniak-Kohn BB. Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. <i>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.<\/i>, <b>5<\/b>, 205\u2013218 (2013).","DOI":"10.1002\/wnan.1211"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kov\u00e1\u010dik A, Kope\u010dn\u00e1 M, V\u00e1vrov\u00e1 K. Permeation enhancers in transdermal drug delivery: benefits and limitations. <i>Expert Opin. Drug Deliv.<\/i>, <b>17<\/b>, 145\u2013155 (2020).","DOI":"10.1080\/17425247.2020.1713087"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Higo N. The recent trend of transdermal drug delivery system development. <i>Yakugaku Zasshi<\/i>, <b>127<\/b>, 655\u2013662 (2007).","DOI":"10.1248\/yakushi.127.655"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. <i>Adv. Drug Deliv. Rev.<\/i>, <b>56<\/b>, 619\u2013658 (2004).","DOI":"10.1016\/j.addr.2003.10.026"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hasan M, Khatun A, Kogure K. Iontophoresis of biological macromolecular drugs. <i>Pharmaceutics.<\/i>, <b>14<\/b>, 525 (2022).","DOI":"10.3390\/pharmaceutics14030525"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kigasawa K, Kajimoto K, Hama S, Saito A, Kanamura K, Kogure K. Noninvasive delivery of siRNA into the epidermis by iontophoresis using an atopic dermatitis-like model rat. <i>Int. J. Pharm.<\/i>, <b>383<\/b>, 157\u2013160 (2010).","DOI":"10.1016\/j.ijpharm.2009.08.036"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Lebwohl M, Freeman A, Chapman MS, Feldman S, Hartle J, Henning A. Proven efficacy of tacrolimus for facial and intertriginous psoriasis. <i>Arch. Dermatol.<\/i>, <b>141<\/b>, 1154 (2005).","DOI":"10.1001\/archderm.141.9.1154"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. <i>Ther. Drug Monit.<\/i>, <b>17<\/b>, 584\u2013591 (1995).","DOI":"10.1097\/00007691-199512000-00007"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Lan CC, Yu HS, Wu CS, Kuo HY, Chai CY, Chen GS. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes <i>via<\/i> regulation of nuclear factor-kappaB. <i>Br. J. Dermatol.<\/i>, <b>153<\/b>, 725\u2013732 (2005).","DOI":"10.1111\/j.1365-2133.2005.06779.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric tacrolimus study group. <i>J. Allergy Clin. Immunol.<\/i>, <b>102<\/b>, 637\u2013644 (1998).","DOI":"10.1016\/S0091-6749(98)70281-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Hanifin JMLong-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. <i>J. Am. Acad. Dermatol.<\/i>, <b>44<\/b> (Suppl.), S58\u2013S64 (2001).","DOI":"10.1067\/mjd.2001.109812"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Bos JD, Meinardi MM. The 500 dalton rule for the skin penetration of chemical compounds and drugs. <i>Exp. Dermatol.<\/i>, <b>9<\/b>, 165\u2013169 (2000).","DOI":"10.1034\/j.1600-0625.2000.009003165.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kajimoto K, Yamamoto M, Watanabe M, Kigasawa K, Kanamura K, Harashima H, Kogure K. Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis. <i>Int. J. Pharm.<\/i>, <b>403<\/b>, 57\u201365 (2011).","DOI":"10.1016\/j.ijpharm.2010.10.021"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hama S, Kimura Y, Mikami A, Shiota K, Toyoda M, Tamura A, Nagasaki Y, Kanamura K, Kajimoto K, Kogure K. Electric stimulus opens intercellular spaces in skin. <i>J. Biol. Chem.<\/i>, <b>289<\/b>, 2450\u20132456 (2014).","DOI":"10.1074\/jbc.M113.514414"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Toyota H, Asai T, Oku N. Process optimization by use of design of experiments: application for liposomalization of FK506. <i>Eur. J. Pharm. Sci.<\/i>, <b>102<\/b>, 196\u2013202 (2017).","DOI":"10.1016\/j.ejps.2017.03.007"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Fukuta T, Oshima Y, Michiue K, Tanaka D, Kogure K. Non-invasive delivery of biological macromolecular drugs into the skin by iontophoresis and its application to psoriasis treatment. <i>J. Control. Release<\/i>, <b>323<\/b>, 323\u2013332 (2020).","DOI":"10.1016\/j.jconrel.2020.04.044"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Opal SM, DePalo VA. Anti-inflammatory cytokines. <i>Chest<\/i>, <b>117<\/b>, 1162\u20131172 (2000).","DOI":"10.1378\/chest.117.4.1162"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) H\u00e4nel KH, Cornelissen C, L\u00fcscher B, Baron JM. Cytokines and the skin barrier. <i>Int. J. Mol. Sci.<\/i>, <b>14<\/b>, 6720\u20136745 (2013).","DOI":"10.3390\/ijms14046720"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. <i>Nature<\/i>, <b>445<\/b>, 866\u2013873 (2007).","DOI":"10.1038\/nature05663"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kajimoto K, Yamamoto M, Watanabe M, Kigasawa K, Kanamura K, Harashima H, Kogure K. Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis. <i>Int. J. Pharm.<\/i>, <b>403<\/b>, 57\u201365 (2011).","DOI":"10.1016\/j.ijpharm.2010.10.021"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Walunj M, Doppalapudi S, Bulbake U, Khan W. Preparation, characterization, and <i>in vivo<\/i> evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. <i>J. Liposome Res.<\/i>, <b>30<\/b>, 68\u201379 (2020).","DOI":"10.1080\/08982104.2019.1593449"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Javia A, Misra A, Thakkar H. Liposomes encapsulating novel antimicrobial peptide Omiganan: Characterization and its pharmacodynamic evaluation in atopic dermatitis and psoriasis mice model. <i>Int. J. Pharm.<\/i>, <b>624<\/b>, 122045 (2022).","DOI":"10.1016\/j.ijpharm.2022.122045"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Dai Y, Zhou R, Liu L, Lu Y, Qi J, Wu W. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): <i>in vitro<\/i> characterization and improved corneal permeation. <i>Int. J. Nanomedicine<\/i>, <b>8<\/b>, 1921\u20131933 (2013).","DOI":"10.2147\/IJN.S44487"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Xu W, Ling P, Zhang T. Toward immunosuppressive effects on liver transplantation in rat model: tacrolimus loaded poly (ethylene glycol)-poly (d, l-lactide) nanoparticle with longer survival time. <i>Int. J. Pharm.<\/i>, <b>460<\/b>, 173\u2013180 (2014).","DOI":"10.1016\/j.ijpharm.2013.10.035"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00667\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T03:17:46Z","timestamp":1705720666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00667\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b23-00667","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"article-number":"b23-00667"}}